leflunomide has been researched along with Pulmonary Alveolar Proteinosis in 1 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Pulmonary Alveolar Proteinosis: A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present a case of biopsy-proven pulmonary alveolar proteinosis in a patient undergoing therapy with the disease-modifying antirheumatoid arthritis drug leflunomide (Arava; Aventis Pharmaceuticals, Bridgewater, NJ)." | 3.73 | Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. ( Miller, R; Wardwell, NR; Ware, LB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wardwell, NR | 1 |
| Miller, R | 1 |
| Ware, LB | 1 |
1 other study available for leflunomide and Pulmonary Alveolar Proteinosis
| Article | Year |
|---|---|
Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Male; Pulmonary | 2006 |